Actelion to Present Data on Novel PAH Drug at ACC Congress on March 15, 2015
Actelion Ltd. will present the latest data from its pivotal phase III trial to evaluate selexipag (Uptravi) for the treatment of pulmonary arterial hypertension (PAH) at the American College of Cardiology (ACC) Congress, which is taking place on March 15 in San Diego. The company…